Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) today announced that the Company had begun dosing healthy volunteer subjects in a first-in-human phase ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE